117 related articles for article (PubMed ID: 21969501)
1. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Chibaudel B; Bonnetain F; Shi Q; Buyse M; Tournigand C; Sargent DJ; Allegra CJ; Goldberg RM; de Gramont A
J Clin Oncol; 2011 Nov; 29(31):4199-204. PubMed ID: 21969501
[TBL] [Abstract][Full Text] [Related]
2. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
[TBL] [Abstract][Full Text] [Related]
3. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
4. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
6. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
7. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Masi G; Vasile E; Loupakis F; Cupini S; Fornaro L; Baldi G; Salvatore L; Cremolini C; Stasi I; Brunetti I; Fabbri MA; Puglisi M; Trenta P; Granetto C; Chiara S; Fioretto L; Allegrini G; Crinò L; Andreuccetti M; Falcone A
J Natl Cancer Inst; 2011 Jan; 103(1):21-30. PubMed ID: 21123833
[TBL] [Abstract][Full Text] [Related]
12. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Allegra C; George T; Yothers G
J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
[No Abstract] [Full Text] [Related]
13. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
14. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A
Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798
[TBL] [Abstract][Full Text] [Related]
15. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
de Gramont A; Buyse M; Abrahantes JC; Burzykowski T; Quinaux E; Cervantes A; Figer A; Lledo G; Flesch M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; Tournigand C
J Clin Oncol; 2007 Aug; 25(22):3224-9. PubMed ID: 17664470
[TBL] [Abstract][Full Text] [Related]
16. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
Seligmann JF; Fisher D; Smith CG; Richman SD; Elliott F; Brown S; Adams R; Maughan T; Quirke P; Cheadle J; Seymour M; Middleton G
Ann Oncol; 2017 Mar; 28(3):562-568. PubMed ID: 27993800
[TBL] [Abstract][Full Text] [Related]
17. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
[TBL] [Abstract][Full Text] [Related]
18. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
Sidhu R; Rong A; Dahlberg S
Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]